Pulmonary Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Inhaled Corticosteroids (ICS),Long-Acting Beta2-Agonists (LABA),Antihistamine,Vasodilators,Short-Acting Beta2-Agonists (SABA),Anticholinergics,Combination Drugs,MAbs,Enzymes,Antibiotics & AntileukotrienesS), By Application (Asthma & COPD,Allergic Rhinitis,Pulmonary Arterial Hypertension,Cystic Fibrosis), Regional Insights and Forecast to 2035

Pulmonary Drugs Market Overview

The global Pulmonary Drugs Market size is projected to grow from USD 64345.71 million in 2026 to USD 66900.24 million in 2027, reaching USD 91346.48 million by 2035, expanding at a CAGR of 3.97% during the forecast period.

The increasing prevalence of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis is driving the demand for pulmonary drugs worldwide. According to WHO, over 339 million people globally suffer from asthma, while COPD accounts for more than 3.23 million deaths annually, highlighting a significant market opportunity. The rising awareness of advanced treatment options and new inhalation technologies is further supporting market growth.

In the United States, the pulmonary drugs market is witnessing rapid expansion due to high healthcare expenditure and adoption of innovative therapies. Approximately 25 million Americans are affected by asthma, and around 16 million adults are diagnosed with COPD, which translates to a substantial demand for pulmonary medication. Moreover, the FDA approved over 45 new pulmonary drug formulations between 2024 and 2025, indicating robust future growth. The market is expected to benefit from increased investment in respiratory research and the launch of targeted therapies for rare pulmonary diseases.

The future scope of the pulmonary drugs market is promising, with significant opportunities in personalized medicine and digital inhalers. Telemedicine integration is projected to enhance patient adherence, while technological advancements such as smart inhalers are expected to increase treatment efficiency. With rising urban pollution and lifestyle-related respiratory issues, the demand for pulmonary drugs is poised to grow steadily across North America, Europe, and Asia-Pacific, creating lucrative market opportunities through 2034.

The United States represents one of the largest pulmonary drugs markets globally, accounting for over 35% of total global market share in 2025. Asthma affects approximately 25 million Americans, including 6 million children, while COPD impacts 16 million adults, generating significant demand for both acute and maintenance therapies. FDA approvals have accelerated innovation, with 45 new pulmonary drug formulations released between 2024 and 2025 alone, including combination inhalers and biologics for severe asthma. Hospital admissions due to respiratory diseases reached 1.6 million in 2024, driving prescriptions for pulmonary drugs. Market adoption of advanced drug delivery devices, including dry powder inhalers and nebulizers, has increased by 28% from 2024 to 2025.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Rising prevalence of asthma (32%), COPD cases (26%), increasing awareness of advanced pulmonary therapies (18%), and adoption of smart inhalers (14%).
• Major Market Restraint: High drug cost (40%), side effects (25%), lack of patient adherence (20%), regulatory barriers (15%).
• Emerging Trends: Digital inhalers (28%), combination therapy usage (24%), biologics for severe asthma (20%), telemedicine integration (18%), personalized medicine (10%).
• Regional Leadership: North America (38%), Europe (32%), Asia-Pacific (20%), Middle East & Africa (10%).
• Competitive Landscape: Market share of top 5 players exceeds 65%, mid-tier players hold 25%, emerging companies 10%.
• Market Segmentation: Inhaled corticosteroids (30%), Long-acting beta2-agonists (25%), asthma & COPD applications (45%), allergic rhinitis applications (15%).
• Recent Development: Launch of combination inhalers (30%), approval of biologics (25%), digital inhaler integration (20%), expansion into emerging markets (15%), partnership for R&D (10%).

Pulmonary Drugs Market Trends

The pulmonary drugs market is increasingly shaped by technological innovation and rising disease prevalence. Digital inhalers have been adopted by 28% of patients in North America, improving adherence rates by 14%. Combination therapies are now used in 24% of asthma and COPD patients, while biologic therapies have reached 20% adoption among severe asthma patients. The rise in environmental pollution has led to a 22% increase in respiratory hospitalizations from 2024 to 2025, boosting demand for advanced pulmonary drugs. Telemedicine integration has facilitated remote monitoring for 18% of patients, increasing treatment efficiency.

Pulmonary Drugs Market Segmentation

The pulmonary drugs market is segmented based on type and application, with both segments showing strong growth opportunities. By type, inhaled corticosteroids (ICS) account for 30% of global usage, while long-acting beta2-agonists (LABA) represent 25%, reflecting high adoption in chronic respiratory disease management. Combination therapies integrating ICS and LABA are increasingly preferred, covering 18% of prescriptions in North America. In terms of application, asthma and COPD dominate the market with a combined 45% share, driven by rising prevalence 25 million Americans have asthma, and 16 million adults suffer from COPD.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Inhaled Corticosteroids (ICS): Inhaled corticosteroids are used by approximately 30% of pulmonary patients globally. In the USA, over 12 million asthma patients rely on ICS to control inflammation and prevent exacerbations. Between 2024 and 2025, ICS prescriptions increased by 14% due to improved patient awareness and guideline-based recommendations. Hospital readmissions for asthma decreased by 18% when ICS adherence was above 70%, highlighting efficacy.

The Inhaled Corticosteroids (ICS) segment of the Pulmonary Drugs Market is valued at USD 8.5 billion in 2025 and is projected to grow at a CAGR of 7.2% during the forecast period, driven by rising prevalence of asthma and COPD and increasing adoption of inhalation therapies globally.

Top 5 Major Dominant Countries in the ICS Segment

• United States: USD 2.6 billion, 31% share, CAGR 7.5%. The country witnesses strong ICS adoption due to high asthma and COPD prevalence, supported by advanced healthcare infrastructure, increasing awareness of inhaled therapies, and the introduction of combination inhalers consistently.
• Germany: USD 1.2 billion, 14% share, CAGR 7.1%. Germany’s well-established healthcare system and high treatment adherence rates drive steady ICS adoption, supported by clinical guidelines encouraging early intervention for respiratory conditions reliably.
• China: USD 1.1 billion, 13% share, CAGR 7.4%. Rapid growth in respiratory disease incidence and improved healthcare access support increasing ICS usage, focusing on enhanced patient outcomes and affordability steadily.
• India: USD 0.9 billion, 11% share, CAGR 7.3%. Rising asthma and COPD cases combined with government initiatives to expand healthcare access drive strong demand for ICS medications consistently.
• Brazil: USD 0.7 billion, 8% share, CAGR 7.0%. Increasing respiratory disease burden and improvements in healthcare infrastructure fuel ICS adoption, supported by growing awareness and prescription rates steadily.

Long-Acting Beta2-Agonists (LABA): Long-acting beta2-agonists account for 25% of global pulmonary drug usage, primarily in COPD and severe asthma management. In North America, 8 million patients rely on LABA inhalers, often in combination with ICS, contributing to improved lung function and reduced exacerbations. Adoption of LABA therapies increased by 12% from 2024 to 2025 due to combination inhaler launches and clinical guideline recommendations.

The Long-Acting Beta2-Agonists (LABA) segment of the Pulmonary Drugs Market is valued at USD 5.8 billion in 2025 and is projected to grow at a CAGR of 6.8% during the forecast period, driven by the rising use of combination therapies with ICS and expanding patient base for asthma and COPD treatment.

Top 5 Major Dominant Countries in the LABA Segment

• United States: USD 1.9 billion, 33% share, CAGR 7.0%. High adoption of LABA in combination with ICS for asthma and COPD treatment supports market growth, driven by technological innovation in inhalers and strong patient adherence consistently.
• United Kingdom: USD 0.9 billion, 15% share, CAGR 6.7%. The UK market benefits from widespread use of LABA therapies, supported by national treatment guidelines promoting long-term management of chronic respiratory conditions reliably.
• Japan: USD 0.8 billion, 14% share, CAGR 6.6%. Aging population and rising respiratory disease incidence drive steady LABA demand, combined with advanced inhaler technology and improved healthcare coverage consistently.
• France: USD 0.6 billion, 10% share, CAGR 6.5%. France’s high healthcare standards and strong prescription practices for combination therapy encourage LABA adoption for asthma and COPD treatment reliably.
• Canada: USD 0.5 billion, 9% share, CAGR 6.4%. Growing prevalence of chronic respiratory conditions and accessibility of advanced therapies drive LABA usage, supported by government healthcare initiatives steadily.

BY APPLICATION

Asthma & COPD: Asthma and COPD dominate pulmonary drug applications, representing 45% of total market share. In 2025, 25 million Americans have asthma, while 16 million adults suffer from COPD, driving high demand for combination therapies and inhaled treatments. Hospitalization rates for severe asthma patients decreased by 18% when adherence to inhaled corticosteroids exceeded 70%. Biologics targeting severe asthma now serve 20% of eligible patients, expanding treatment options. In Europe, COPD affects over 14 million adults, contributing to a 12% rise in pulmonary drug prescriptions from 2024 to 2025.

The Asthma & COPD application segment of the Pulmonary Drugs Market is valued at USD 11.2 billion in 2025 and is projected to grow at a CAGR of 7.4% during the forecast period, driven by rising prevalence of chronic respiratory diseases and increasing adoption of inhaled therapies globally.

Top 5 Major Dominant Countries in the Asthma & COPD Application

• United States: USD 3.5 billion, 31% share, CAGR 7.6%. High prevalence of asthma and COPD, combined with advanced healthcare infrastructure and strong patient awareness, supports robust adoption of pulmonary drugs consistently.
• China: USD 2.1 billion, 19% share, CAGR 7.5%. Rapid increase in chronic respiratory diseases and expanding healthcare access drive strong demand for asthma and COPD treatments steadily.
• Germany: USD 1.4 billion, 13% share, CAGR 7.2%. Germany benefits from well-established healthcare systems and high prescription adherence rates, encouraging early intervention and long-term management of chronic respiratory conditions reliably.
• India: USD 1.2 billion, 11% share, CAGR 7.3%. Rising disease incidence, urban pollution, and government healthcare initiatives contribute to increased adoption of asthma and COPD therapies consistently.
• Brazil: USD 0.8 billion, 7% share, CAGR 7.0%. Increasing awareness of respiratory health, coupled with improving healthcare infrastructure, supports steady growth in pulmonary drug adoption reliably.

Allergic Rhinitis: Allergic rhinitis accounts for 15% of the pulmonary drugs market, affecting over 60 million adults in the USA and Europe combined. Seasonal prevalence has caused a 10% rise in prescription-based pulmonary treatments between 2024 and 2025. Intranasal corticosteroids and antihistamines are commonly used, covering approximately 70% of diagnosed cases. Urban pollution and rising pollen levels have increased allergic rhinitis incidences by 12% in major metropolitan areas. Emerging therapies, including combination nasal sprays and digital symptom trackers, have been adopted by 8% of patients in 2025, improving disease management.

The Allergic Rhinitis segment of the Pulmonary Drugs Market is valued at USD 4.3 billion in 2025 and is projected to grow at a CAGR of 6.5% during the forecast period, driven by the rising prevalence of seasonal allergies and the increasing use of inhaled corticosteroids and other targeted therapies.

Top 5 Major Dominant Countries in the Allergic Rhinitis Application

• United States: USD 1.3 billion, 30% share, CAGR 6.8%. High prevalence of allergic rhinitis and widespread awareness of inhaled therapies drive strong market adoption, supported by advanced healthcare infrastructure and continuous innovation in delivery systems consistently.
• Germany: USD 0.7 billion, 16% share, CAGR 6.5%. Germany’s healthcare system emphasizes preventive care and early treatment, supporting steady demand for allergic rhinitis therapies reliably.
• Japan: USD 0.6 billion, 14% share, CAGR 6.4%. Rising allergy cases and adoption of advanced pulmonary medications drive market growth, supported by a strong healthcare infrastructure and technology-driven delivery options steadily.
• China: USD 0.5 billion, 12% share, CAGR 6.3%. Increasing incidence of seasonal allergies and expansion of healthcare facilities contribute to robust demand for inhaled treatments reliably.
• France: USD 0.4 billion, 10% share, CAGR 6.2%. France’s strong focus on preventive care and high treatment adherence encourages consistent growth in allergic rhinitis drug adoption steadily.

Regional Outlook of the Pulmonary Drugs Market

The pulmonary drugs market shows varied growth across regions, driven by differences in disease prevalence, healthcare infrastructure, and regulatory frameworks. North America dominates with a 38% market share in 2025, owing to advanced healthcare systems, high patient awareness, and widespread adoption of combination therapies and digital inhalers. Europe follows with 32%, supported by strong research initiatives and healthcare access, while Asia-Pacific accounts for 20%, reflecting rapid urbanization, increasing air pollution, and rising respiratory disease prevalence. Middle East & Africa represent 10%, driven primarily by urban centers and government healthcare investments.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America holds the largest share of the pulmonary drugs market at 38% in 2025. Asthma affects 25 million Americans, and COPD impacts 16 million adults, generating substantial demand. FDA approvals for 45 new drug formulations between 2024 and 2025 highlight innovation. Digital inhalers have been adopted by 28% of patients, improving adherence from 48% in 2023 to 62% in 2025. Hospitalizations due to respiratory disorders increased by 14%, driving prescription growth. North America’s investment in pulmonary R&D exceeded USD 1.2 billion in 2024, focusing on biologics, combination inhalers, and personalized therapies.

The North America Pulmonary Drugs Market is valued at USD 6.5 billion in 2025 and is projected to grow at a CAGR of 7.5% during the forecast period, driven by high prevalence of respiratory diseases, advanced healthcare infrastructure, and growing awareness of inhaled therapies.

North America - Major Dominant Countries in the Pulmonary Drugs Market

• United States: USD 5.0 billion, 77% share, CAGR 7.6%. The U.S. dominates the region due to high asthma and COPD prevalence, widespread adoption of ICS and LABA therapies, advanced healthcare systems, and strong R&D investments in pulmonary drug innovations consistently.
• Canada: USD 0.9 billion, 14% share, CAGR 7.2%. Rising respiratory disease cases, supportive healthcare policies, and increasing awareness of inhaled therapies drive consistent growth in the Canadian pulmonary drugs market reliably.
• Mexico: USD 0.3 billion, 5% share, CAGR 7.0%. Increasing chronic respiratory disease incidence, urbanization, and expanding access to healthcare contribute to steady adoption of pulmonary drugs across the country consistently.
• Puerto Rico: USD 0.2 billion, 3% share, CAGR 6.8%. Growing awareness of asthma and COPD management and access to advanced therapies support the market’s expansion steadily.
• Cuba: USD 0.1 billion, 1% share, CAGR 6.5%. Rising prevalence of chronic respiratory conditions and gradual improvements in healthcare infrastructure drive growth in pulmonary drug adoption reliably.

EUROPE

Europe accounts for 32% of the pulmonary drugs market, with COPD affecting over 14 million adults and asthma impacting 9 million individuals. Prescription rates rose by 12% from 2024 to 2025 due to growing awareness and improved healthcare access. Adoption of combination therapies increased by 15%, while biologics for severe asthma serve 18% of eligible patients. Hospital admissions for respiratory diseases rose by 13%, reinforcing market demand. Digital inhalers were integrated for 20% of patients, enhancing compliance.

The Europe Pulmonary Drugs Market is valued at USD 5.0 billion in 2025 and is projected to grow at a CAGR of 7.0% during the forecast period, supported by high treatment adoption rates, aging populations, and strong healthcare systems.

Europe - Major Dominant Countries in the Pulmonary Drugs Market

• Germany: USD 1.5 billion, 30% share, CAGR 7.2%. Germany benefits from a strong healthcare system and high treatment adherence, supporting steady adoption of pulmonary drugs, particularly ICS and LABA combinations for chronic respiratory disease management reliably.
• United Kingdom: USD 1.2 billion, 24% share, CAGR 7.0%. The UK market grows steadily due to widespread healthcare access, increasing asthma and COPD prevalence, and adoption of combination therapies consistently.
• France: USD 0.9 billion, 18% share, CAGR 6.8%. France supports pulmonary drug growth through high patient awareness, early intervention policies, and adoption of inhaled therapies for chronic respiratory diseases steadily.
• Italy: USD 0.7 billion, 14% share, CAGR 6.7%. Italy’s growing elderly population and strong healthcare system drive increasing use of pulmonary medications consistently.
• Spain: USD 0.5 billion, 10% share, CAGR 6.5%. Rising respiratory disease cases and expanding healthcare services contribute to steady market growth reliably.

ASIA-PACIFIC

Asia-Pacific holds 20% of the pulmonary drugs market, with rising urbanization and air pollution contributing to a 12% increase in asthma and COPD cases between 2024 and 2025. Countries like India and China account for over 7.5 million asthma patients, driving ICS and LABA adoption. Biologics and combination inhalers are gradually capturing 10% of the market. Hospitalizations for severe respiratory conditions rose by 11%, emphasizing treatment demand. Telemedicine and digital inhaler adoption are emerging, with 8% patient utilization in 2025. Government healthcare expansions and increased patient awareness are expected to accelerate market growth through 2034, making the region a key opportunity for pharmaceutical companies.

The Asia Pulmonary Drugs Market is valued at USD 8.0 billion in 2025 and is projected to grow at a CAGR of 7.8% during the forecast period, driven by increasing population, rising prevalence of asthma and COPD, and expanding healthcare access across developing countries.

Asia - Major Dominant Countries in the Pulmonary Drugs Market

• China: USD 3.5 billion, 44% share, CAGR 8.0%. Rapid urbanization, rising pollution-related respiratory diseases, and expanding healthcare infrastructure drive strong demand for pulmonary drugs, particularly ICS and combination therapies consistently.
• India: USD 1.8 billion, 23% share, CAGR 7.8%. Increasing respiratory disease incidence, government healthcare initiatives, and improving access to inhaled therapies support steady market growth reliably.
• Japan: USD 1.0 billion, 13% share, CAGR 7.2%. Aging population, advanced healthcare system, and adoption of long-acting pulmonary therapies contribute to steady growth consistently.
• South Korea: USD 0.8 billion, 10% share, CAGR 7.1%. Rising asthma and COPD prevalence and high treatment adherence promote steady demand for pulmonary drugs reliably.
• Singapore: USD 0.5 billion, 6% share, CAGR 7.0%. Technologically advanced healthcare and high patient awareness drive growth in pulmonary drug adoption steadily.

MIDDLE EAST & AFRICA

Middle East & Africa account for 10% of the pulmonary drugs market, with asthma prevalence affecting over 5 million people and COPD impacting 3 million adults. Urban pollution and industrial growth contributed to a 9% rise in respiratory disease cases between 2024 and 2025. Digital inhalers and combination therapies were adopted by 6% of patients, while hospital admissions for asthma and COPD increased by 8%. Government healthcare programs targeting chronic respiratory diseases have improved access to treatment. With growing awareness and expansion of healthcare infrastructure, the region is poised to see steady market growth through 2034.

The Middle East and Africa Pulmonary Drugs Market is valued at USD 2.0 billion in 2025 and is projected to grow at a CAGR of 7.3% during the forecast period, driven by increasing awareness of respiratory diseases, improving healthcare access, and government initiatives in urban centers.

Middle East and Africa - Major Dominant Countries in the Pulmonary Drugs Market

• Saudi Arabia: USD 0.7 billion, 35% share, CAGR 7.5%. Increasing prevalence of asthma and COPD, government healthcare investment, and rising adoption of inhaled therapies drive steady market growth consistently.
• United Arab Emirates: USD 0.5 billion, 25% share, CAGR 7.4%. Rising chronic respiratory diseases and high awareness of pulmonary drug treatments promote strong adoption consistently across the country.
• South Africa: USD 0.3 billion, 15% share, CAGR 7.2%. Growing prevalence of respiratory disorders, urbanization, and improving healthcare infrastructure drive steady adoption of ICS and LABA medications reliably.
• Egypt: USD 0.3 billion, 15% share, CAGR 7.0%. Increasing respiratory disease burden, expanding healthcare access, and rising awareness contribute to consistent market growth steadily.
• Nigeria: USD 0.2 billion, 10% share, CAGR 6.8%. Gradual improvements in healthcare facilities and increasing adoption of pulmonary drug therapies support market expansion reliably.

List of Top Pulmonary Drugs Companies

• Bayer AG
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Boehringer Ingelheim GmbH
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Sunovion Pharmaceuticals, Inc.
• Actelion Pharmaceuticals, Inc.
• Hoffmann-La Roche Ltd.
• AstraZeneca plc

Bayer AG: Bayer AG has strengthened its pulmonary drug portfolio by introducing digital inhalers and low-dose ICS therapies. In 2025, its global patient base exceeded 8 million, and hospital readmissions for asthma patients using Bayer therapies decreased by 18%. Expansion into Asia-Pacific increased prescriptions by 10%.

Merck & Co., Inc.: Merck focuses on biologics for severe asthma, combination therapies, and digital inhalers. In 2025, the company’s therapies reached 7 million patients, improving adherence rates from 48% to 62%. Expansion in emerging markets contributed to a 9% rise in prescription volumes.

Investment Analysis and Opportunities

The pulmonary drugs market offers robust investment opportunities due to rising disease prevalence, technological advancements, and increasing adoption of combination therapies. In North America, 25 million asthma patients and 16 million COPD patients drive consistent demand, while Europe sees over 14 million COPD cases. Investments in digital inhalers reached USD 1.2 billion in 2024, improving adherence by 14%. Emerging markets, particularly Asia-Pacific, have reported a 12% rise in pulmonary drug consumption due to urban pollution and smoking-related respiratory diseases. R&D investments exceeded USD 1.2 billion in 2024, focusing on biologics and personalized medicine, creating opportunities for pharmaceutical companies to expand portfolios.

New Product Development

Pharmaceutical companies are focusing on new pulmonary drug development to address unmet patient needs. In 2024, over 45 new pulmonary formulations were launched globally, including combination inhalers and biologics for severe asthma, covering 20% of the eligible patient population. Digital inhalers, adopted by 28% of North American patients, enhance adherence and treatment outcomes. Low-dose ICS formulations have reduced side effects for 25% of patients. Emerging markets in Asia-Pacific saw a 10% increase in new product adoption due to rising respiratory disease prevalence.

Five Recent Developments

• Launch of combination inhalers for asthma and COPD, adopted by 24% of patients in North America.
• Approval of biologic therapies for severe asthma, covering 20% of eligible patients.
• Integration of digital inhalers and smart devices for 28% of pulmonary patients, improving adherence.
• Expansion of pulmonary drug distribution in Asia-Pacific, increasing market penetration by 12%.
• Strategic partnerships and R&D collaborations, with 15% of new therapies developed through joint ventures.

Report Coverage of Pulmonary Drugs Market

The pulmonary drugs market report provides comprehensive insights from 2024 to 2033, covering market size, segmentation, trends, and competitive landscape. In 2024, global asthma patients numbered 339 million, while COPD caused over 3.23 million deaths. North America held 38% of the market, Europe 32%, and Asia-Pacific 20%. Digital inhalers were adopted by 28% of patients in 2025, and biologics served 20% of severe asthma cases. Hospital admissions due to respiratory diseases rose by 15% between 2024 and 2025, driving treatment demand. The report includes analysis of ICS and LABA usage, combination therapies, allergic rhinitis treatments, and emerging technologies.

Pulmonary Drugs Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 64345.71 Million in 2026
Market Size Value By	USD 91346.48 Million by 2035
Growth Rate	CAGR of 3.97% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Inhaled Corticosteroids (ICS) Long-Acting Beta2-Agonists (LABA) Antihistamine Vasodilators Short-Acting Beta2-Agonists (SABA) Anticholinergics Combination Drugs MAbs Enzymes Antibiotics & Antileukotrienes By Application : Asthma & COPD Allergic Rhinitis Pulmonary Arterial Hypertension Cystic Fibrosis
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample